| Document |
Document Title |
|
WO/2020/157194A1 |
The present invention includes name compounds of general formula (I) : (I) in which R1, R2, R3 and R4 are as defined herein, methods for their preparation, pharmaceutical compositions and combinations comprising said compounds, and their...
|
|
WO/2020/144030A1 |
The present invention relates to a process for the synthesis of organosulfate salts of amino acid esters comprising the steps of reacting at least one lactam with at least 3 carbon atoms in the lactam ring with sulfuric acidin an aqueous...
|
|
WO/2020/145627A1 |
Provided is a method for preparing glufosinate, comprising the steps of: preparing a first intermediate compound by reacting L-homoserine in the presence of a first acid catalyst; preparing a second intermediate compound by reacting the ...
|
|
WO/2020/146568A1 |
A method for the synthesis of diazabicyclo[6.2.0]decane compounds is provided. The synthesis proceeds by stereoselective synthesis of a chiral lactone followed by azetidine formation via a series of chemoselective reactions. Bicyclizatio...
|
|
WO/2020/141141A1 |
The invention relates to novel cocrystals of (R)-Baclofen and processes for preparation thereof, and in particular to cocrystals of (R)-Baclofen with cinnamic acid, benzoic acid, salicylic acid and ferulic acid. It also refers to pharmac...
|
|
WO/2020/140309A1 |
The present invention provides a method for preparing a 3-hydroxybutyrate amino acid salt compound, comprising: (1) adding ethyl 3-hydroxybutyrate or methyl 3-hydroxybutyrate into a reaction vessel, taking water as a solvent, adding a ba...
|
|
WO/2020/134137A1 |
The present application relates to the field of drug synthesis, and disclosed thereby is a method for synthesizing R-3-chloroalanine methyl ester hydrochloride, comprising the following steps: 1) allowing d-serine to react with paraforma...
|
|
WO/2020/127349A1 |
The present invention relates to a crumbly phase composition containing on total weight of the composition (i) 70 – 87 wt% of organic compounds and salts thereof containing 85 to 100 wt% on total organic compounds and salts thereof of ...
|
|
WO/2020/126647A1 |
The invention relates to a process for preparing a monolysinate compound (200, 300, 400, 500, 600, 700, 800, 900). The process comprises a provision (502) of a liquid reaction mixture (810), in which lysin (802) and a metal salt (404) ar...
|
|
WO/2020/130856A1 |
Disclosed are metal organic frameworks (MOFs) for adsorbing guest species, methods for the separation of gases using the MOFs, and systems comprising the MOFs. The MOFs comprise a plurality of secondary building units (SBUs), each SBU co...
|
|
WO/2020/120637A1 |
The application relates to a compound of formula (I) or a pharmaceutical salt thereof of formula (II), as well as to a process to obtain said compound and a process to obtain said salt. Additionally disclosed is the compound of formula (...
|
|
WO/2020/122182A1 |
The present inventor found that the membrane permeability of a peptide compound can be improved by employing at least one amino acid which has a side chain capable of forming an intermolecular hydrogen bond, as one of the amino acids con...
|
|
WO/2020/107500A1 |
The present invention provides a 2-(1-acyloxypentyl) benzoic acid salt formed by basic amino acid or aminoguanidine, a preparation method thereof, a pharmaceutical preparation containing the salt and the uses of the pharmaceutical prepar...
|
|
WO/2020/109938A1 |
The present application relates to improved processes for the preparation of Sitagliptin and pharmaceutically acceptable salts thereof. The present application also relates to the improved crystallization process for the preparation of S...
|
|
WO/2020/102737A1 |
Disclosed herein are compounds and methods for labeling and quantifying analytes using mass spectrometry.
|
|
WO/2020/095983A1 |
It was discovered that a cyclic sulfamidate could be produced by reacting an aminoacid derivative with a cyclization reagent. In addition, it was discovered that an O-substituted serine derivative could be produced by reacting the cyclic...
|
|
WO/2020/087794A1 |
The present application discloses an F-18 labeled 5-aminolevulinic acid derivative, a synthesis method therefor, and an application thereof. A radioactive probe provided in an implementation of the present application has a long radioact...
|
|
WO/2020/086816A1 |
The present invention relates to compounds and methods useful for selectively modulating mTORC1 activity.
|
|
WO/2020/080120A1 |
Provided is a polar compound having high chemical stability, high ability to orient liquid crystal molecules, high solubility with respect to a liquid crystal composition, and a high voltage holding ratio of a liquid crystal display elem...
|
|
WO/2020/081852A1 |
The present disclosure provides compositions that inhibit the SH2-containing inositol 5'-phosphatase (SHIP), as well as methods using such compositions for use in treating or ameliorating the effects of a medical condition in a subject.
|
|
WO/2020/074964A1 |
The present disclosure relates to compounds of the general formula (I): wherein R1, R2, R3, R4, R5, R6, and R7 may be chosen from different substituents; n is 0, 1, or 2; and X is a hydroxymethyl or a carboxylic acid or a derivative ther...
|
|
WO/2020/075007A1 |
Provided is an addition-fragmentation agent of the formula (I) where Ramine comprises a tertiary amine group; R2 linking group of valence a+2; Z is an ethylenically unsaturated polymerizable group; and subscript a is 0 or 1.
|
|
WO/2020/072605A1 |
The disclosure provides ionizable amine lipids and salts thereof (e.g., pharmaceutically acceptable salts thereof) useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepa...
|
|
WO/2020/070508A1 |
An amorphous form of a chelating agent is provided, in particular wherein the chelating agent comprises ethylenediaminetetraacetic acid/edetic acid (EDTA), diethylenetriaminepentaacetic acid/pentetic acid (DTPA), nitrilotriacetic acid (N...
|
|
WO/2020/065319A1 |
A composition comprising a keto acid compound and an acid-generating agent, wherein the keto acid compound is capable of transitioning from a non-coloured state to a coloured state, the transition being effected by the application of an ...
|
|
WO/2020/069176A1 |
A substrate composition for leukocyte esterases comprising a monoester, said monoester being one of an α-amino acid ester or an α-hydroxy acid ester, with specificity for leukocyte esterases, said monoester having a first moiety for pa...
|
|
WO/2020/056582A1 |
Disclosed are a method for purifying a bis-dicarboxylic diamino platinum derivative, and a product obtained from the method. The purification method comprises: dissolving dicarboxylic acid in water to obtain a first solution, heating sam...
|
|
WO/2020/061367A1 |
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...
|
|
WO/2020/044121A1 |
Described herein are cannabinoid formulations in combination with phenylalanine for oral administration. Further described herein are methods for orally administering one or more cannabinoids to a subject in need thereof and manufacturin...
|
|
WO/2020/047035A1 |
The present disclosure provides, inter alia, methods of treating cancer by administering an effective amount of a compound of Formula (I). In some embodiments, the cancer is a solid cancer. In some embodiments, the cancer is melanoma. In...
|
|
WO/2020/046975A1 |
Described herein are methods of treating or preventing an ASK1 or DYRK1A associated disease, disorder, or condition comprising administering to a subject in need thereof a dual inhibitor of ASK1 and DYRK1A; including administering pharma...
|
|
WO/2020/038583A1 |
The present invention relates to a composition comprising a photosensitizer use in prevention or treatment of dermatological disease in a patient, wherein the composition is used in the following order of steps: (a) topical application o...
|
|
WO/2020/041301A1 |
Compounds, methods of use, and processes for making inhibitors of complement factor D or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the ...
|
|
WO/2020/039631A1 |
Disclosed is a compound represented by formula (1): Q-CHR2 (1) (in the formula, Q represents a nitrogen-containing aliphatic group that includes two or more tertiary nitrogen atoms, and does not include oxygen, and R represents an alipha...
|
|
WO/2020/035011A1 |
Provided are a method for preparing 18F-BPA and an intermediate. High-purity 18F-BPA can be obtained by means of the method, which simplifies synthesis steps after 18F labeling, with simple operation and high efficiency.
|
|
WO/2020/032184A1 |
The present invention provides: a technique of allowing an active component, particularly nucleic acid, to be introduced into a cell with excellent efficiency; and a cationic lipid, etc., for use in the technique. The cationic lipid acco...
|
|
WO/2020/031201A1 |
The present invention relates to highly pure 6-aminohexanoic acid of formula-1 which is free of organic volatile impurities, caprolactam impurity and improved process for its preparation thereof. The present invention also relates to an ...
|
|
WO/2020/029762A1 |
A preparation method for a fused tricyclic γ-amino acid derivative and an intermediate thereof, and a method for preparing an intermediate of the fused tricyclic γ-amino acid derivative. The fused tricyclic γ-amino acid derivative has...
|
|
WO/2020/028988A1 |
A method is for use with a treatment regime that includes the exposure of a patient to THC. The method comprises the step of administering Theanine to the patient. The Theanine can be L-Theanine. The treatment regime can involve a plural...
|
|
WO/2020/028222A1 |
Compounds and methods are provided for the treatment of neurological or mitochondrial diseases, including epilepsy. In some embodiments, the compounds are substituted 1,4- naphthoquinones.
|
|
WO/2020/024763A1 |
Provided are a photocurable hydrophilic polymer, a coating composition based thereon, a hydrophilic lubricant coating, and a product. The photocurable hydrophilic polymer is formed by the copolymerization of a polymerizable photosensitiv...
|
|
WO/2020/025789A1 |
The present invention relates to salts of elafibranor.
|
|
WO/2020/028221A1 |
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the en...
|
|
WO/2020/021077A1 |
The present invention relates to processes for the preparation of polymorphic form D2 of robenacoxib and to pharmaceutical formulations thereof. The polymorphic form of robenacoxib obtained by the processes of the present invention is ch...
|
|
WO/2020/023311A1 |
Processes for preparing neutral liposomes include adding a hydrophobic solution of liposome lipid bilayer precursors and a nucleic acid condenser to an aqueous composition of a nucleic acid condenser and a biologically active ingredient ...
|
|
WO/2020/011258A1 |
Provided are a crystal form of a salt of a fused tricyclic γ-amino acid derivative and the preparation and use thereof. As shown in formula (I), Y is selected from maleic acid, fumaric acid, haloid acid (preferably hydrobromic acid and ...
|
|
WO/2020/011257A1 |
Disclosed are a pharmaceutical composition of a fused tricyclic γ-amino acid derivative and the use thereof. The pharmaceutical composition comprises: (i) the structure as shown in formula (I) or a pharmaceutically acceptable salt there...
|
|
WO/2020/007839A1 |
The present inventionrefers to a crystalline salt comprising5-methyl-(6S)-tetrahydrofolic acid L-leucine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid and L-leucine ethyl ester is from 1:0.3 to 1:3.0 (in mol/m...
|
|
WO/2020/007841A1 |
The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester is from 1:0.3 to 1:3.0 (in m...
|
|
WO/2020/007836A1 |
The present invention is directed to a crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid and L-isoleucine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to L-isoleucine ethyl ester is from 1:0.3 to 1:2.0 (...
|
